OJEMDA™ (tovorafenib)
Pediatric low-grade glioma (pLGG) with BRAF alterations
ApprovedCommercial; Phase 2 follow-up data ongoing
Key Facts
Indication
Pediatric low-grade glioma (pLGG) with BRAF alterations
Phase
Approved
Status
Commercial; Phase 2 follow-up data ongoing
Company
About Day One Biopharmaceuticals
Founded in 2018, Day One Biopharmaceuticals is driven by a mission to creatively and intentionally develop new medicines for people of all ages with life-threatening diseases, starting from the urgent needs of children with cancer. The company achieved a landmark FDA approval in 2024 for OJEMDA™ in pediatric low-grade glioma (pLGG) and is actively expanding its pipeline through strategic acquisitions, such as Mersana Therapeutics. With a leadership team of seasoned oncology experts, Day One employs a nimble, patient-centric business model to identify, develop, and commercialize first- or best-in-class targeted oncology therapies.
View full company profile